Goldstein, D.J., Lu, Y., Detke, M.J., Lee, T.C. and Iyengar, S. (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116, 109-118. doi:10.1016/j.pain.2005.03.029

has been cited by the following article:

• TITLE: Erratum to “Addition of Metanx in Pregabalin Partial Responders for Painful Diabetic Neuropathy”

  AUTHORS: Allen Mark Jacobs, Dunlei Cheng

  KEYWORDS: L-Methylfolate; Methylcobalamin; Metanx; Diabetic Neuropathy

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.4 No.3, August 29, 2014

  ABSTRACT: Objective: To study the effect of addition of Metanxon burning parasthesias in patients with symptomatic diabetic neuropathy who had obtained only partial symptom resolution with pregabalin. Research design and methods: This was an open-label pilot study. There were 16 patients (7 males, 9 females) in the study group and 8 patients (3 males, 5 females) in the control group. A patient numeric rating scale (0 - 10) of neuropathy associated pain was obtained atbaseline and at 20 weeks. The control group continued on a fixed dosage of pregabalin without additional medication, while the study group was supplemented with Metanx(a proprietary blend of bioactive B-vitamins), in addition to being continued on a fixed dosage of pregabalin. Results:After 20 weeks, significantly more patients in the study group experienced pain relief compared to the control group (87.5% vs. 12.5%, respectively, p=0.005). The average pain score reduction after 20 weeks in the study group was 3 compared to0.25 inthe control group (p may be used for the relief of pain in patients that have obtained only partial resolution of symptomatology from pregabalin.